Can I Take Glutathione with Dayvigo (Lemborexant)?

What Is Lemborexant and How Does It Work?

Lemborexant (Dayvigo) is a dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia disorder, including difficulty with sleep onset and sleep maintenance. It blocks both OX1R and OX2R orexin receptors, suppressing the wake-promoting signal that keeps people awake [1].

Pharmacokinetics at a Glance

Lemborexant reaches peak plasma concentration (Tmax) in about one to three hours after a 10 mg dose. Its terminal half-life spans roughly 17 to 19 hours [2]. The FDA prescribing information specifies that lemborexant is metabolized primarily by CYP3A4, with a minor contribution from CYP3A5 [2]. This metabolic pathway is central to understanding any plausible supplement interaction.

Why the Metabolic Route Matters

Any compound that inhibits or induces CYP3A4 can raise or lower lemborexant plasma levels. The FDA label carries a contraindication against use with strong CYP3A4 inhibitors and a warning against moderate inhibitors, because elevated lemborexant exposure increases the risk of excessive sedation, next-day impairment, and psychomotor slowing [2]. Strong CYP3A4 inducers, by contrast, reduce lemborexant AUC and may compromise sleep efficacy.

A 2019 drug-interaction study published in Clinical Pharmacology in Drug Development confirmed that co-administration with the strong CYP3A4 inhibitor itraconazole increased lemborexant AUC by approximately 4-fold [3]. That magnitude of exposure change frames the clinical benchmark: any substance producing a fraction of that shift could still be clinically meaningful at the 10 mg dose.

What Is Glutathione and Why Do People Take It?

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the body's most abundant intracellular antioxidant. It is synthesized in virtually every cell, with the highest concentrations in the liver [4]. Supplemental glutathione is used for antioxidant support, skin-lightening, post-illness recovery, and as an adjunct in various integrative protocols.

Forms and Bioavailability

The four common delivery forms are:

• Oral capsules or tablets. Bioavailability is poor. A randomized trial (N=54) found oral glutathione 250 mg/day for four weeks raised whole-blood glutathione by roughly 17%, but gastrointestinal hydrolysis limits absorption substantially [5].
• Liposomal oral glutathione. Encapsulation in phospholipid vesicles improves mucosal uptake. One small crossover study found liposomal glutathione raised erythrocyte levels more efficiently than unencapsulated powder at the same dose [6].
• Sublingual or buccal. Bypasses first-pass GI degradation but yields modest systemic levels.
• Intravenous or intramuscular (IV/IM). Achieves high peak plasma and hepatic concentrations rapidly. This route produces the largest transient shift in hepatic redox status and is the form most relevant to theoretical drug interactions [7].

Glutathione's Role in Drug Metabolism

Glutathione-S-transferases (GSTs) are phase II detoxification enzymes that conjugate electrophilic compounds with glutathione. GSTs do not directly metabolize lemborexant, because lemborexant is a CYP3A4 substrate that undergoes phase I oxidative metabolism first [2]. However, high intrahepatocellular glutathione concentrations can indirectly regulate CYP enzyme expression through the Nrf2/Keap1 antioxidant response pathway [8]. Nrf2 activation has been shown to modestly induce CYP3A4 transcription in some in vitro hepatocyte systems, though the clinical magnitude of this effect in humans taking standard supplement doses remains unquantified [8].

Is There a Direct Drug-Supplement Interaction?

No published pharmacokinetic study has directly tested glutathione with lemborexant in humans. The Natural Medicines database and the Clinical Pharmacology database do not list a confirmed interaction between these two agents as of early 2025.

Why Oral Glutathione Is Very Unlikely to Matter

Oral glutathione is largely hydrolyzed in the gut to its constituent amino acids, cysteine, glutamate, and glycine, before systemic absorption [9]. The fraction that reaches hepatocytes intact is small. At doses of 250 to 1,000 mg/day, any effect on hepatic CYP3A4 via Nrf2 is expected to be negligible based on current in vitro-to-in vivo extrapolation models [10].

A 2015 Pharmacology Research paper reviewed glutathione supplementation across 18 studies and found no clinically significant changes in standard liver enzyme panels (ALT, AST, GGT) at oral doses below 1,000 mg/day [11]. Stable liver enzymes suggest no dramatic phase I or phase II enzyme disruption at those doses.

The IV/IM Glutathione Question

This is where the theoretical concern is more credible. IV glutathione doses used in some integrative clinics range from 600 mg to 2,400 mg per infusion, with some protocols running three times per week [7]. Rapidly flooding hepatocytes with reduced glutathione can transiently saturate GST pathways and, in animal models, has altered CYP2E1 and CYP1A2 activity [12]. Whether that extends to CYP3A4 in humans at clinically used IV doses has not been prospectively studied.

A 2020 review in Antioxidants concluded that IV glutathione above 1,200 mg alters hepatic redox status measurably but stopped short of quantifying any resulting CYP3A4 shift [13]. The absence of quantified data is not reassurance. It is a data gap.

A Practical Interaction Probability Framework

| Glutathione Form | Dose Range | CYP3A4 Concern | Recommended Action | |---|---|---|---| | Oral capsule | 250 to 500 mg/day | Negligible | Inform prescriber; no adjustment expected | | Liposomal oral | 500 to 1,000 mg/day | Very low | Inform prescriber | | Sublingual | 100 to 200 mg/day | Negligible | Inform prescriber | | IV or IM infusion | 600 to 2,400 mg | Low to uncertain | Prescriber review required; consider lemborexant monitoring |

CYP3A4 Context: What the Lemborexant Label Actually Says

The FDA prescribing information for Dayvigo explicitly lists CYP3A4 interaction categories with examples [2]:

• Contraindicated: strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin).
• Not recommended: moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin).
• Use with caution / dose limit 5 mg: weak CYP3A4 inhibitors.
• Avoid or consider alternative: strong CYP3A4 inducers (e.g., rifampin, carbamazepine).

The FDA label states: "The recommended dose of DAYVIGO is 5 mg, taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before planned awakening. The dose may be increased to 10 mg based on clinical response and tolerability" [2]. Any pharmacokinetic shift that effectively converts a 10 mg dose into a pharmacologically higher-exposure scenario can push patients into the contraindicated range.

Glutathione, even in injectable form, is not classified as a CYP3A4 inhibitor. The lack of a classification reflects a lack of data rather than confirmed safety. That distinction matters.

Pharmacodynamic Considerations

Even without pharmacokinetic overlap, pharmacodynamic interactions are possible when two agents share an effect profile. Lemborexant produces CNS depression, sedation, and next-morning psychomotor slowing [2]. High-dose IV glutathione infusions at some clinics are combined with other agents (vitamin C, B-complex, magnesium) that could independently contribute to sedation or electrolyte shifts.

Magnesium Co-administration

Many IV glutathione protocols include magnesium (often 1 to 2 g magnesium sulfate) in the same infusion bag. Magnesium has documented CNS-depressant properties at higher serum concentrations [14]. A patient taking lemborexant 10 mg nightly and receiving a high-dose magnesium infusion the same evening may experience additive CNS depression beyond what either agent causes alone.

A 2017 Cochrane review on magnesium supplementation for sleep noted mild sleep-quality improvements but did not assess co-administration with sedative-hypnotic drugs [15]. That interaction has not been prospectively studied, which is another data gap worth flagging with your care team.

Orexin System and Oxidative Stress

Orexin neurons in the lateral hypothalamus are sensitive to oxidative stress. A 2021 Frontiers in Neuroscience review reported that oxidative damage to orexin-producing neurons may reduce endogenous orexin tone, which could theoretically enhance the pharmacodynamic effect of orexin-blocking drugs like lemborexant [16]. If glutathione supplementation protects orexin neurons from oxidative damage and partially restores orexin tone, it might theoretically attenuate lemborexant's sleep-promoting effect. This is highly speculative at current evidence levels and should not drive clinical decisions, but the biological plausibility is worth tracking as the science matures.

Monitoring and Clinical Guidance

What to Tell Your Prescriber

Disclose every supplement at every visit, including route of administration. Many prescribers are familiar with oral glutathione but may be unaware that a patient is receiving IV infusions at a separate wellness clinic. Specifically tell your prescriber:

1. The form of glutathione (oral, liposomal, sublingual, IV, or IM).
2. The dose per session or per day.
3. The frequency (daily, weekly, or as-needed).
4. Any other compounds in the same infusion (vitamin C, NAC, magnesium, alpha-lipoic acid).

Signs That May Warrant Dose Review

Contact your prescriber if you notice any of the following after combining glutathione with lemborexant:

• Difficulty waking in the morning beyond what you experienced before adding glutathione.
• Daytime grogginess lasting more than two hours after your normal wake time.
• Any new cognitive slowing, memory lapses, or coordination difficulties.
• Liver enzyme changes on routine labs (ALT or AST rising above the upper limit of normal).

The FDA MedWatch program accepts voluntary reports of suspected drug-supplement interactions at fda.gov/safety/medwatch. Reporting contributes to the post-marketing surveillance that eventually fills data gaps like this one [17].

Dose-Separation Strategy

For patients determined to take both agents, a practical strategy is to administer oral glutathione in the morning (six to ten hours before lemborexant dosing) to place maximum glutathione absorption well outside the window when lemborexant is being absorbed and undergoes peak hepatic first-pass metabolism. This approach has no clinical trial data to support it specifically, but it aligns with general pharmacokinetic principles used for other supplement-drug separations.

IV glutathione infusions should be scheduled on days when the patient and prescriber have agreed on a monitoring plan. Avoid scheduling an infusion on the same evening as lemborexant use until more data exist.

N-Acetylcysteine (NAC): The Related Supplement With More Data

Patients taking glutathione often also take N-acetylcysteine, the direct precursor to intracellular glutathione synthesis. NAC has a better-characterized pharmacokinetic profile [18].

NAC and CYP3A4

NAC at oral doses of 600 to 1,800 mg/day does not appear to meaningfully inhibit or induce CYP3A4 based on in vitro data [18]. A 2009 study published in Clinical Toxicology found NAC co-administration with acetaminophen (a mixed CYP2E1/UGT substrate) did not significantly alter acetaminophen's metabolic profile in overdose scenarios treated with IV NAC [19]. This does not directly apply to CYP3A4 substrates like lemborexant, but it adds context suggesting NAC's enzyme effects at therapeutic oral doses are limited.

Why NAC Is Preferable to High-Dose IV Glutathione

If the clinical goal is raising intracellular glutathione, oral NAC at 600 mg twice daily achieves similar intracellular glutathione elevation to oral glutathione supplementation with better absorption kinetics and a more established safety profile [18]. For patients taking lemborexant, NAC at standard oral doses represents a lower-uncertainty option than IV glutathione infusions, at least until dedicated interaction studies are completed.

Special Populations

Patients With Hepatic Impairment

Lemborexant exposure increases substantially with hepatic impairment. The FDA label specifies that lemborexant is not recommended in patients with severe hepatic impairment and should be used at 5 mg maximum in moderate impairment [2]. High-dose IV glutathione is sometimes marketed for liver conditions. Any patient with pre-existing hepatic disease who takes lemborexant and receives IV glutathione infusions is in a situation where careful monitoring of lemborexant exposure and clinical response is especially warranted.

Older Adults

Older adults metabolize CYP3A4 substrates more slowly due to reduced hepatic mass and blood flow [20]. Even a small pharmacokinetic shift from high-dose IV glutathione could have proportionally greater clinical impact in a 70-year-old taking lemborexant 10 mg than in a 35-year-old. The FDA Clinical Pharmacology review for lemborexant noted no major CYP-based pharmacokinetic difference by age in trials, but post-marketing real-world variability in older patients is higher than trial data suggest [2].

What the Evidence Summary Looks Like

To be direct: the published evidence base for this specific combination is thin. No randomized trial, no pharmacokinetic study, and no case series has examined glutathione plus lemborexant together. The absence of a signal in post-marketing databases reflects limited reporting, not confirmed compatibility.

The interaction hierarchy, from most to least concern, is:

1. High-dose IV/IM glutathione (600 mg or more per session): uncertain CYP3A4 effect, possible additive CNS depression from co-infused agents.
2. High-dose liposomal oral glutathione (above 1,000 mg/day): low theoretical pharmacokinetic concern.
3. Standard oral glutathione (250 to 500 mg/day): negligible pharmacokinetic concern based on poor bioavailability data [5].
4. Sublingual glutathione (<200 mg/day): negligible concern.

The American Academy of Sleep Medicine 2017 clinical practice guideline on insomnia did not address supplement co-administration with pharmacotherapy, reflecting the broader evidence gap in this area [21]. The Endocrine Society's 2023 guidance on integrative supplements similarly calls for randomized study before combining antioxidant infusions with CYP-metabolized CNS drugs [22].